Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.

Authors:
Simge Acar Amy E Armstrong Angela C Hirbe

Expert Opin Investig Drugs 2022 Jan 28;31(1):31-40. Epub 2021 Dec 28.

Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

Introduction: Neurofibromatosis Type 1 (NF1) is an autosomal dominant genetic condition, which predisposes individuals to the development of plexiform neurofibromas (PN), benign nerve sheath tumors seen in 30-50% of patients with NF1. These tumors may cause significant pain and disfigurement or may compromise organ function. Given the morbidity associated with these tumors, therapeutic options for patients with NF1-related PN are necessary.

Areas Covered: We searched the www.clinicaltrials.gov database for 'plexiform neurofibroma.' This article summarizes completed and ongoing trials involving systemic therapies for PN.

Expert Opinion: Surgery is the mainstay treatment; however, complete resection is not possible in many cases. Numerous systemic therapies have been evaluated in patients with NF1, with MEK inhibitors (MEKi) showing the greatest efficacy for volumetric reduction and improvement in functional and patient-reported outcomes. The MEKi selumetinib is now FDA approved for the treatment of inoperable, symptomatic PN in pediatric NF1 patients. Questions remain regarding the use of this drug class in terms of when to initiate therapy, overall duration, reduced dosing schedules, and side effect management. Future studies are needed to fully understand the clinical application of MEKi and to evaluate other potential therapies through appropriate trial designs for this potentially devastating, manifestation in NF1.

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2022.2022120DOI Listing
January 2022

Publication Analysis

Top Keywords

systemic therapies
8
patients nf1
8
nf1
5
cases numerous
4
numerous systemic
4
therapies evaluated
4
evaluated patients
4
nf1 mek
4
mek inhibitors
4
inhibitors meki
4
manifestation nf1
4
meki showing
4
showing greatest
4
greatest efficacy
4
efficacy volumetric
4
volumetric reduction
4
reduction improvement
4
improvement functional
4
functional patient-reported
4
resection cases
4

Keyword Occurance

Similar Publications

Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.

Authors:
James Isaacs Thomas E Stinchcombe

Drugs 2022 May 21. Epub 2022 May 21.

Division of Medical Oncology, Duke Cancer Institute, Duke University Medical Center, DUMC 3841, Durham, NC, 27710, USA.

Approximately a third of patients with non-small-cell lung cancer (NSCLC) present with surgically resectable disease. Patients who undergo surgical resection are at a high risk of relapse, and neoadjuvant and adjuvant chemotherapy improves disease-free survival (DFS) and overall survival (OS). The outcomes with neoadjuvant and adjuvant chemotherapy are similar, and both are used in clinical practice. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

New Topical Therapies in Development for Atopic Dermatitis.

Authors:
Egídio Freitas Melinda Gooderham Tiago Torres

Drugs 2022 May 21. Epub 2022 May 21.

Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.

Atopic dermatitis (AD) is a common chronic pruritic inflammatory cutaneous disease. AD is characterized by intense pruritus and enormous clinical heterogeneity. Treatment goals are to improve skin lesions and minimize exacerbations and symptom burden. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Local problems need global solutions - the metabolic needs of regenerating organisms.

Authors:
Ines C Kübler Jenny Kretzschmar Marko Brankatschk Tatiana Sandoval-Guzmán

Wound Repair Regen 2022 May 21. Epub 2022 May 21.

Department of Internal Medicine III, Center for Healthy Aging, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

The vast majority of species that belong to the plant or animal kingdom evolved with two main strategies to counter tissue damage - scar formation and regeneration. Whereas scar formation provides a fast and cost-effective repair to exit life-threatening conditions, complete tissue regeneration is time-consuming and requires vast resources to reinstall functionality of affected organs or structures. Local environments in wound healing are widely studied and findings have provided important biomedical applications. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Review article: Latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-Risks, screening, diagnosis and management.

Authors:
Sasha R Fehily Aysha H Al-Ani Jonathan Abdelmalak Clarissa Rentch Eva Zhang Justin T Denholm Douglas Johnson Siew C Ng Vishal Sharma David T Rubin Peter R Gibson Britt Christensen

Aliment Pharmacol Ther 2022 May 20. Epub 2022 May 20.

Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.

Background: One quarter of the world's population has latent tuberculosis infection (LTBI). Systemic immunosuppression is a risk factor for LTBI reactivation and the development of active tuberculosis. Such reactivation carries a risk of significant morbidity and mortality. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Celastrol mitigates inflammation in sepsis by inhibiting the PKM2-dependent Warburg effect.

Authors:
Piao Luo Qian Zhang Tian-Yu Zhong Jia-Yun Chen Jun-Zhe Zhang Ya Tian Liu-Hai Zheng Fan Yang Ling-Yun Dai Chang Zou Zhi-Jie Li Jing-Hua Liu Ji-Gang Wang

Mil Med Res 2022 May 20;9(1):22. Epub 2022 May 20.

Artemisinin Research Center, and Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, 100700, China.

Background: Sepsis involves life-threatening organ dysfunction and is caused by a dysregulated host response to infection. No specific therapies against sepsis have been reported. Celastrol (Cel) is a natural anti-inflammatory compound that shows potential against systemic inflammatory diseases. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap